EUVIMEDObjevte EUVIMED
Systematische Übersicht

Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis

Abdulkareem Jomaa iD, Mohammed Alani, Bilind Ismail, Dani Hayder, Rani Bshara, Rafil Bshara iD, Wasim Jomaa, Abdullah Al-Ibraheem, Hasan Al-Obaidi, Hrishikesh Samant

Diabetes, Obesity and Metabolism · 2026-11-03

DOI: 10.1111/dom.71497 ↗

At a glance

Systematische Übersicht in Diabetes, Obesity and Metabolism, published online on 2026-11-03. Written by Abdulkareem Jomaa and 9 co-authors. Institution: Department of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq. 27 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Aims Compensated MASH cirrhosis is an advanced disease with no current approved pharmacologic therapy. FGF analogues have shown biological activity, but individual trials have not established histologic efficacy. We aim to evaluate their effects across histologic and non‐invasive outcomes in this population.

Methods

PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched from inception through 8 July 2026 for RCTs comparing FGF analogues with placebo in adults with compensated (F4) MASH cirrhosis. The primary outcome was at least 1‐stage fibrosis improvement without MASH worsening. Secondary outcomes included Pro‐C3, Enhanced Liver Fibrosis (ELF) score and liver stiffness. MASH resolution and safety were exploratory. Random‐effects meta‐analyses were performed. RoB 2 and GRADE assessments were conducted.

Results

Five RCTs involving 589 participants were included. FGF analogues did not significantly improve fibrosis by at least one stage without worsening of MASH (RR, 1.32; 95% CI, 0.89–1.97). In post hoc exploratory analyses, FGF21 analogues increased MASH resolution alone (RR, 3.17; 95% CI, 1.49–6.73), whereas resolution without worsening of fibrosis remained inconclusive (RR, 1.75; 95% CI, 0.95–3.23). Treatment reduced ELF score (MD, −0.52; 95% CI, −0.79 to −0.25), Pro‐C3 (MD, −26.49 percentage points; 95% CI, −40.47 to −12.51) and liver stiffness (MD, −2.30 kPa; 95% CI, −3.90 to −0.71). Serious adverse events were not significantly increased, but adverse‐event‐related discontinuation was more frequent (RR, 3.44; 95% CI, 1.13–10.43). FGF19 findings derive from a single trial (aldafermin).

Conclusions

FGF analogues did not significantly improve the primary fibrosis endpoint, but improved MASH resolution and non‐invasive fibrosis measures, supporting continued evaluation of FGF analogues in Phase 3 trials with longer follow‐up.

Subjects

Author keywords

compensated cirrhosisfibroblast growth factor analoguesliver fibrosis regressionmetabolic dysfunction‐associated steatohepatitis (MASH)non‐invasive fibrosis biomarkers

Authors and institutions

  • Department of Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan Region, Iraq.
  • Department of Internal Medicine, Midwestern University, Glendale, Arizona, USA.
  • Department of Internal Medicine, Willis-Knighton Health System, Shreveport, Louisiana, USA.
  • College of Medicine, University of Zakho, Zakho Independent Administration, Kurdistan Region, Iraq.
  • Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Gastroenterology and Hepatology, University of Toledo, Toledo, Ohio, USA.

ORCID profiles: Abdulkareem Jomaa, Rafil Bshara

Cite

APA

Jomaa, A., Alani, M., Ismail, B., Hayder, D., Bshara, R., Bshara, R., Jomaa, W., Al-Ibraheem, A., Al-Obaidi, H., & Samant, H. (2026). Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71497

Vancouver

Jomaa A, Alani M, Ismail B, Hayder D, Bshara R, Bshara R, et al. Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71497

BibTeX
@article{Jomaa2026,
  author = {Jomaa, Abdulkareem and Alani, Mohammed and Ismail, Bilind and Hayder, Dani and Bshara, Rani and Bshara, Rafil and Jomaa, Wasim and Al-Ibraheem, Abdullah and Al-Obaidi, Hasan and Samant, Hrishikesh},
  title = {Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71497}
}
Start for free →